Mediclinic Durbanville Cardiac Unit
Dr_Marshall_Heradien_Web
Mediclinic Durbanville Cardiac Unit

Dr Marshall Heradien

Specialities
Cardiologist

Core competencies

Dr Heradien is an experienced Interventional Cardiologist with a special interest in Refractory hypertension, Interventional renal ablation therapy and Atrial fibrillation.

Profile

HPCRegNo
MP0448664
PracticeNo
0180031809660

Qualification

1995
MBCHB, University of Stellenbosch
2008
Cert Cardiology (SA), Colleges of Medicine

Contact

Marshall Heradien
Physical Address:
Lompré House, Loerie Park, 15 Paul Kruger street, Durbanville, 7550
021 979 0910
cardiologists@wandb.co.za

Practices at

Publications & videos

  1. Heradien M, Mahfoud F, Greyling C, et al. Renal Denervation prevents subclinical atrial fibrillation in patients with hypertensive heart disease: randomized, sham- controlled trial. Heart Rhythm. 2022 Jun 30:S1547-5271(22)02160-9. doi: 10.1016/j.hrthm.2022.06.031. Epub ahead of print.
  2. Heradien MJ. Renal denervation-a practical approach based on the latest clinical evidence. Heart Matters. October 2021; Volume 12; 3: 11-12.
  3. Schwartz PJ, Moreno C, Kotta MC, Pedrazzini M, Crotti L, Dagradi F, Castelletti S, Haugaa KH, Denjoy I, Shkolnikova MA, Brink PA, Heradien MJ, Seyen SRM, Spätjens RLHMG, Spazzolini C, Volders PGA. Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. Eur Heart J. 2021 Sep 10:ehab582. doi 10.1093/eurheartj/ehab582. Epub ahead of print. PMID: 34505893.
  4. Dippenaar AP, Van der Bijl P, Heradien MJ, Saaiman A. Percutaneous left atrial appendage occlusion in South Africa. S Afr Med J. 2021 Jun 30;111(7):13337.
  5. Kraus SM, Shaboodien G, Francis V, et al.; IMHOTEP Investigators. Rationale and design of the African Cardiomyopathy and Myocarditis Registry Program: The IMHOTEP study. Int J Cardiol. 2021 Jun 15;333:119-126.
  6. Heradien MJ, Van der Bijl P, Brink PA. Renal Denervation in South Africa. S Afr Med J. 2020 Jan 29;110(2):12841.
  7. Rayner B, Ntsekhe M, Cassel G, Ebrahim I, Heradien M, Mpe M. Position Statement on Renal Denervation in South Africa 2020. www.hypertension.org.za
  8. Sibeko SS, Heradien MJ, Van Der Bijl P, et al. Renal Denervation: Impact on Non-ST Segment Elevation Myocardial Infarction Rates in Patients With Hypertensive Heart Disease. Circulation. 2020 Nov 17;142(Suppl_3):A14713.
  9. Heradien MJ, Van Der Bijl P, Brink PA. Renal Denervation: mechanisms and clinical aspects. African Journal of Nephrology, 23(1):19-24.
  10. Heradien M, Mahfoud F, Hettrick D, Brink P. Renal denervation: dark past, bright future? Cardiovasc J Afr. 2019 Sep/Oct;30(5):290-296.
  11. Gerstein HC, Colhoun HM, Dagenais GR, et al.; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo- controlled trial. Lancet. 2019 Jul 13;394(10193):121-130.
  12. Gerstein HC, Colhoun HM, Dagenais GR, et al.; REWIND Investigators. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomized, placebo- controlled trial. Lancet. 2019 Jul 13;394(10193):131-138.
  13. Crotti L, Lahtinen AM, Spazzolini C, Mastantuono E, Cristina Monti M, Morassutto C, Parati G, Heradien M, et al. Response by Crotti et al. to Letter Regarding Article, "Genetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3' Untranslated Region of KCNQ1?". Circ Cardiovasc Genet. 2016 Dec;9(6):581-582.
  14. Crotti L, Lahtinen AM, Spazzolini C, Mastantuono E, Cristina Monti M, Morassutto C, Parati G, Heradien M, et al. Response by Crotti, et al. to Letter Regarding Article, "Genetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3' Untranslated Region of KCNQ1?". Circ Cardiovasc Genet. 2016 Dec;9(6):581-582.
  15. Heradien MJ, Augustyn J, Saaiman A, Brink PA. First reported cases: renal Denervation with a second-generation multi-electrode catheter via brachial and radial access. Cardiovasc J Afr. 2016 Jan-Feb;27(1):53-5.
  16. van der Bijl P, Heradien M, Doubell A, Brink P. QTc prolongation prior to angiography predicts poor outcome and associates significantly with lower left ventricular ejection fractions and higher left ventricular end-diastolic pressures. Cardiovasc J Afr. 2012 Nov;23(10):541-5.
  17. Crotti L, Spazzolini C, Porretta AP, Dagradi F, Taravelli E, Petracci B, Vicentini A, Pedrazzini M, La Rovere MT, Vanoli E, Goosen A, Heradien M, George AL Jr, Brink PA, Schwartz PJ. Vagal reflexes following an exercise stress test: a simple clinical tool for gene-specific risk stratification in the long QT syndrome. J Am Coll Cardiol. 2012 Dec 18;60(24):2515-24.
  18. Carstens N, van der Merwe L, Revera M, Heradien M, Goosen A, Brink PA, Moolman-Smook JC. Genetic variation in angiotensin II type 2 receptor gene influences extent of left ventricular hypertrophy in hypertrophic cardiomyopathy independent of blood pressure. J Renin Angiotensin Aldosterone Syst. 2011 Sep;12(3):274-80.
  19. Heradien M, Revera M, van der Merwe L, Goosen A, Corfield VA, Brink PA, Mayosi BM, Moolman-Smook JC. Abnormal blood pressure response to exercise occurs more frequently in hypertrophic cardiomyopathy patients with the R92W troponin T mutation than in those with myosin mutations. Heart Rhythm. 2009 Nov;6(11 Suppl):S18-24.
  20. van der Merwe L, Cloete R, Revera M, Heradien M, Goosen A, Corfield VA, Brink PA, Moolman-Smook JC. Genetic variation in angiotensin-converting enzyme 2 gene is associated with extent of left ventricular hypertrophy in hypertrophic cardiomyopathy. Hum Genet. 2008 Aug;124(1):57-61.
  21. Schwartz PJ, Vanoli E, Crotti L, Spazzolini C, Ferrandi C, Goosen A, Hedley P, Heradien M, Bacchini S, Turco A, La Rovere MT, Bartoli A, George AL Jr, Brink PA. Neural control of heart rate is an arrhythmia risk modifier in long QT syndrome. J Am Coll Cardiol. 2008 Mar 4;51(9):920-9.
  22. Revera M, van der Merwe L, Heradien M, Goosen A, Corfield VA, Brink PA, Moolman-Smook JC. Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy. Cardiovasc Res. 2008 Mar 1;77(4):687-94.
  23. Heradien M, Goosen A, Moolman-Smook JC, Brink PA. Race and gender representation of hypertrophic cardiomyopathy or long QT syndrome cases in a South African research setting. Cardiovasc J Afr. 2007 Sep-Oct;18(5):312-5.
  24. Revera M, Van der Merwe L, Heradien M, Goosen A, Corfield VA, Brink PA, Moolman-Smook JC. Long-term follow-up of R403WMYH7 and R92WTNNT2 HCM families: mutations determine left ventricular dimensions but not wall thickness during disease progression. Cardiovasc J Afr. 2007 May-Jun;18(3):146-53.
  25. Heradien MJ, Goosen A, Crotti L, Durrheim G, Corfield V, Brink PA, Schwartz PJ. Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation? J Am Coll Cardiol. 2006 Oct 3;48(7):1410-5.
  26. Brink PA, Crotti L, Corfield V, Goosen A, Durrheim G, Hedley P, Heradien M, Geldenhuys G, Vanoli E, Bacchini S, Spazzolini C, Lundquist AL, Roden DM, George AL Jr, Schwartz PJ. Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation. 2005 Oct 25;112(17):2602-10.

Events & lectures